PMID: 8358559Jun 1, 1993

The antiarrhythmic effects of the nucleoside transporter inhibitor, R75231, in anaesthetized pigs

British Journal of Pharmacology
C L WainwrightH Van Belle

Abstract

1. The effect of R75231, an inhibitor of purine nucleoside transport, were examined on ischaemic arrhythmias in anaesthetized pigs. 2. In closed chest pigs (n = 4), R75231 exerted a moderate dose-dependent decrease in mean arterial blood pressure (from 97 +/- 4 mmHg to 95 +/- 4, 90 +/- 1 and 83 +/- 2 mmHg at 25, 50 and 100 micrograms kg-1 respectively) and produced a dose-related shift to the left of the blood pressure dose-response curve to intravenous bolus doses of adenosine. The degree of inhibition of adenosine uptake by R75231, assessed ex vivo in erythrocyte suspensions, was 43 +/- 5%, 64 +/- 13 and 114 +/- 15% at doses of 25, 50 and 100 micrograms kg-1 respectively. 3. In open chest pigs, intravenous injection of R75231 (50 micrograms kg-1; n = 6 and 100 micrograms kg-1; n = 10) induced a dose-related decrease in both systolic and diastolic arterial blood pressure which was more marked than in closed-chest pigs (mean pressure 86 +/- 4 to 70 +/- 2 mmHg and 88 +/- 6 to 60 +/- 6 mmHg with 50 and 100 micrograms kg-1 respectively), without affecting heart rate or myocardial contractility. Coronary artery occlusion in these pigs caused a secondary decrease in blood pressure. This was not observed in controls (n = 10). The low...Continue Reading

References

Aug 1, 1992·Journal of Cardiovascular Pharmacology·H Van BelleJ I Robertson
Oct 1, 1991·British Journal of Pharmacology·F E Parkinson, A S Clanachan
Jul 1, 1990·British Journal of Pharmacology·A D KingE Müller-Schweinitzer
May 1, 1989·International Journal of Cardiology·J B GuptaD S Vyas
Aug 15, 1989·European Journal of Pharmacology·A P IJzermanH Van Belle
Jul 1, 1988·British Journal of Pharmacology·E Karwatowska-ProkopczukA Wennmalm
Jan 12, 1988·European Journal of Pharmacology·C L Wainwright, J R Parratt
Aug 1, 1985·European Heart Journal·A J WoodA J Drake-Holland
Jan 1, 1983·British Journal of Pharmacology·M G Collis
Apr 20, 1984·European Journal of Pharmacology·O Fagbemi, J R Parratt
Jan 1, 1980·British Journal of Pharmacology·K E BlassK Pönicke
Jun 1, 1982·British Journal of Pharmacology·S J CokerJ R Parratt
Nov 1, 1981·Circulation·D S BlumenthalL C Becker
Jan 1, 1993·Journal of Cardiovascular Pharmacology·C L Wainwright, P A Martorana
Jan 1, 1993·Cardiovascular Research·M B FormanE K Jackson

Citations

Apr 1, 1995·Journal of Clinical Pharmacology·G A RongenT Thien
May 1, 1994·British Journal of Pharmacology·M BöhmE Erdmann
Apr 1, 1996·The Journal of Pharmacy and Pharmacology·M J HagertyK A Kane
Feb 18, 2004·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Arthur M Feldman, Charles McTiernan
Jun 29, 2004·European Journal of Pharmacology·Tohru NojiHideaki Kusaka
May 24, 2014·Journal of Cardiovascular Pharmacology and Therapeutics·Ersöz Gonca, Faruk Darıcı
Apr 1, 1997·Journal of Cardiovascular Pharmacology·W Sun, C L Wainwright

Related Concepts

R 88 016
Adenocard
Anesthesia Procedures
Cardiac Depressants
Cardiac Arrhythmia
Diastolic Blood Pressure
Sinus Node Artery
Dose-Response Relationship, Drug
Electrocardiographic Recorders
Nucleosides

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.